@FierceBiotech: Purdue puts up $213M for a novel pain drug from VM Pharma. Report | Follow @FierceBiotech
@JohnCFierce: AstraZeneca nabs priority review voucher as Wellstat bags FDA OK. Report | Follow @JohnCFierce
@DamianFierce: NYT editorial takes a weird, non-systemic middle ground on PCSK9 pricing. Article | Follow @DamianFierce
> Shares of Melbourne, Australia-based Starpharma (ASX: SPL, OTCQX: SPHRY) soared today after the company announced a collaboration with AstraZeneca ($AZN), putting their drug delivery tech to work for the pharma giant. Starpharma grabbed a $2 million upfront with milestones ranging up to $124 million for the first product, with more to come if it extends to additional programs. Release
> Jim Allison, an immuno-oncology expert now at MD Anderson, won the prestigious Lasker-DeBakey Clinical Medical Research Award. Report
> Tampa, FL-based Oxis Biotech inked a license agreement to further develop and commercialize DT2219ARL, a novel therapy for B cell cancers, leukemias and lymphomas. Release
Medical Device News
@FierceMedDev: ICYMI from FierceDiagnostics: Focus Diagnostics gets FDA blessing to expand label for herpes test. Story | Follow @FierceMedDev
@StacyALawrence: ICYMI Friday: Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Article | Follow @StacyALawrence
@EmilyWFierce: ICYMI from FiercePharma: Novartis snags EU approval for multiple myeloma med Farydak. Report | Follow @EmilyWFierce
> GSK-backed SetPoint raises $15M to advance anti-inflammatory, neuromodulation device. Article
> Novartis CEO: Smart contact lenses 'progressing well' with first human trials set for 2016. Report
Pharma News
@FiercePharma: Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. More from FiercePharmaAsia | Follow @FiercePharma
@CarlyHFierce: ICYMI Friday: AstraZeneca scores FDA nod for long-term Brilinta use. Article | Follow @CarlyHFierce
> Perrigo's fate is in shareholders' hands, Mylan chairman says. Or is it? Story
> Roche CEO lashes out at U.K.'s 'stupid' move to stop paying for a dozen-plus cancer meds. More
> Study: Pfizer's Chantix does not increase risk of depression, heart attack in smokers. Report
Animal Health News
> Report: Bees self-medicate to protect against parasites. More
> Nexvet doubles down on R&D spending as net loss widens. Report
> Veterinarian's op-ed piece says antibiotic ban taking tools away from vets. Article
> New mobile app allows virtual veterinary consultations. Item
> UC Davis veterinarian pushes 'One Health' system for scientific literature. Story
Biotech IT News
> NIH commits $49M to fuel fusion of genomic data and EHRs. News
> Labfolder taps investors for cash to develop ELN system. Report
> Thermo Fisher rolls out Ion S5 sequencer in play for clinical trial sector. Story
> CD Genomics adds HiSeq X Ten to suite of tools for sequencing services. Item
> Google hooks up with Sanofi to continue diabetes drive. Article
Drug Delivery News
> Gene therapy approach for T1 diabetes could alter immune system to boost insulin. Report
> Sanofi looking to expand U.K. plant that does contract manufacturing of inhaled meds. Story
> Columbia U. team delivers small liquid drug doses to the lungs for targeted treatment. More
> Study finds e-cigarettes are being used to vaporize pot. Item
> Generic alternative to Novartis' transdermal patch for Alzheimer's hits the market. Article
Pharma Manufacturing News
> Recipharm to buy Alcon plant as part of manufacturing agreement. News
> GSK runs into supply issues after China plant damaged by nearby explosion. More
> MSF warns that Sanofi leaving antivenom market will lead to treatment crisis. Report
> Cipla gets first U.S. manufacturing plant with InvaGen buy. Article
> U.K. generics maker starts plant in Alabama. Story
Pharma Asia News
> Japan's PAFSC gives nods to Takeda's glatiramer, MSD's omarigliptin. News
> Samsung Bioepis wins South Korea nod for SB4, etanercept biosimilar. Story
> India denies Pfizer application for additional Xeljanz patents. More
> Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. Item
> Hutchison MediPharma's fruquintinib notches a second with proof-of-concept result. Article